A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

Darling Ingredients (NYSE:DAR) has had a rough three months with its share price down 9.2%. It seems that the market... IRVING, Texas, February 20, 2025--Darling Ingredients Inc. (NYSE ...

We’re committed to making a Hope education accessible. Disability and Accessibility Resources (DAR) assists the college with its mission of educating students for lives of leadership and service in a ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The national capital remains the ideal location for engaging both domestic and international audiences, says Jaya Asokan, fair director, India… ...

Over the last 14 years, the World ADC team has accompanied the community industry through ups and down while offering the latest insights on how to improve ADC drug development. We take pride in ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...